SU18. GLP-1 Receptor Agonist Treatment in Schizophrenia Patients With Obesity

Autor:	Niklas Rye Jørgensen, Birgitte Fagerlund, Filip K. Knop, Brian V. Broberg, Ulrik B. Andersen, Bjørn H Ebdrup, Nikolaj Bak, Jens J. Holst, Pelle L. Ishøy, Birte Glenthøj
Rok vydání:	2017
Předmět:	0301 basic medicine endocrine system medicine.medical_specialty business.industry digestive oral and skin physiology 030204 cardiovascular system & hematology medicine.disease Obesity Abstracts 03 medical and health sciences Psychiatry and Mental health 030104 developmental biology 0302 clinical medicine Text mining Endocrinology Schizophrenia Internal medicine medicine business hormones hormone substitutes and hormone antagonists Glucagon-like peptide 1 receptor
Zdroj:	Schizophrenia Bulletin. 43:S167-S167
ISSN:	1745-1701 0586-7614
Popis:	Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are registered for treatment of both obesity and type 2 diabetes, and we investigated metabolic and cognitive effects of the GLP-1RA, exenatide once weekly, in nondiabetic, antipsychotic-treated, obese patients with schizophrenia.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae154519f6cbc2d29554524340eb3449 https://doi.org/10.1093/schbul/sbx024.017 Zobrazit plný text záznamu